Wednesday, September 17, 2014 Last update: 2:33 PM
FreshNews.com - All Company Technology News Since 1996

Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference

Companies mentioned in this article: Synthetic Biologics, Inc.

ROCKVILLE, Md., May 20, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 3(rd) Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. Mr. Riley is scheduled to present at 4:30 p.m. (Eastern Time).

http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://wsw.com/webcast/marcum2/syn. After the presentation, a replay will be archived and accessible for 60 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference. Please contact the Marcum conference representative Taline Chalian at taline.chalian@marcumllp.com.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO

SOURCE Synthetic Biologics, Inc.